$ICPT at AASLD -> Ratziu points to data suggesting stat sig NASH resolution achievable in larger study

$ICPT at AASLD -> Vlad Ratziu, Lancet editorial author on FLINT, excited to highlight +ves of 'ground-breaking' data

⁦NASH-TAG Conference⁩ Vlad Ratziu is on right now talking about how to do a trial without biopsy?

Breakthroughs in therapies for NASH‼️

Find about the advances & remaining challenges in this review👉bit.ly/3O2J4pb

By Vlad Ratziu et al.

Part of #BreakthroughsInHepatology
➡️bit.ly/36khmDF

#NonalcoholicSteatohepatitis
#LiverTwitter

#WorldObesityDay
#Obésité #Sarcopénique , découvrez le projet du Pr Jean-Michel Oppert, du Pr Vlad Ratziu, et de Vittoria Zambon qui vise à mettre en place un nouvel outil de #diagnostic basé sur la technologie de l’ #IA .
ihuican.org/journee-mondia…

#Innovation #Sante #recherche

Today, 12.30PM: GENFIT hosts special #NASH #KOL lunch during #EASL #ILC2018 w/ guest speakers Prs./Drs. S. Harrison, V. Ratziu & J. Schattenberg. #NAFLD #NASH #LiverDisease

Really enjoying Vlad Ratziu making the argument for histologic endpoints #NASH

Here highlighting inconsistencies between liver biopsy and NITs in the STELLAR trials

What does it matter if clinical outcomes are not improved?

That is the missing piece in the jigsaw

#ILC2020

'La distribución de la grasa, sin importar el IMC puede afectar la salud del hígado' Dr. Vlad Ratziu

GENFIT ~ #ILC2016 NASH Symposium Vlad D.Ratziu : What New Therapies Are on the Horizon; Efficacy and Safety Profiles

GENFIT organise aujourd'hui une Journée Portes Ouvertes à destination de ses #actionnaires individuels, avec la présence exceptionnelle du Pr Vlad Ratziu, MD. $GNFT

Causes of chronic liver diseases and causea of Cirrhosis in US prof.Vlad Ratziu, MD

Vlad Ratziu shares data on economic burden of NAFLD (via markers like ALT) on society #ILC2016

Alcohol NO! FIbrosis in the general Dutch population older then 45 yrs prof.Vlad Ratziu ,MD

Global prevalence of #NAFLD 25% prof.Vlad Ratziu

Art. Vlad Ratziu International Coordinator of the GOLDEN-505 study #ILC2015 #EASL15 goo.gl/DyglFw p67 $GNFT

On going meeting “Why change name of NAFLD” .. Vlad Ratziu presenting his arguments ⁦AASLD⁩

[ #LiverCancer AwarenessMonth ] #Hepatologist Pr. V. Ratziu, MD, explains that complications for #NASH #patients include #cirrhosis & #LiverCancer .
Watch our #WebTV to learn more about #FattyLiver ➡ the-nash-education-program.com/news-medias/ed…
#NASH edu #NAFLD #LiverDisease #LiverHealth #HCC

Prof. Ratziu: Aramchol, developed in Israel by the late Prof. Tuvia Gilat, shows biochemical, radiological and histological benefit in treating #NASH . Moving to phase 3? AASLD #LiverMtg18

📌 Save the date for the next LiverSeminar!

🗓June 30th 4PM (CET)
➡️ Necroptosis in #NASH
👨🏻‍🔬Speaker: Jérémie Gautheron (Sorbonne Université Inserm)
👨🏻‍⚕️Host: Javier Ampuero (@CIBERehd SeLiver Group IBiS)

With Vlad Ratziu and Manuel Romero-Gómez in the Q&A.